Leukemia & Lymphoma最新文献

Immunoglobulin kinetics and infection patterns across venetoclax-based regimens in chronic lymphocytic leukemia. 免疫球蛋白动力学和感染模式跨venetoclax方案在慢性淋巴细胞白血病。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-20 DOI: 10.1080/10428194.2026.2745238

Tulsi Patel, Nirja Shah, Benjamin Heyman, Thomas Kipps, Michael Choi

引用次数: 0

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study. PTCy、西罗莫司、MMF和RGI-2001探讨单倍体外周血干细胞移植后调节性t细胞扩增：一项初步研究

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-20 DOI: 10.1080/10428194.2026.2747545

Zachariah DeFillipp, Nora K Horick, Kathleen M E Gallagher, Won-Ho Lee, J Graham Kiana, Brittany Diana, Ribeka Gebretsadik, Dana D Lee, Jooho Chung, Areej El-Jawahri, Matthew J Frigault, Steven McAfee, Richard A Newcomb, Paul V O'Donnell, Thomas R Spitzer, Peter Westervelt, Yi-Bin Chen

{"title":"PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.","authors":"Zachariah DeFillipp, Nora K Horick, Kathleen M E Gallagher, Won-Ho Lee, J Graham Kiana, Brittany Diana, Ribeka Gebretsadik, Dana D Lee, Jooho Chung, Areej El-Jawahri, Matthew J Frigault, Steven McAfee, Richard A Newcomb, Paul V O'Donnell, Thomas R Spitzer, Peter Westervelt, Yi-Bin Chen","doi":"10.1080/10428194.2026.2747545","DOIUrl":"https://doi.org/10.1080/10428194.2026.2747545","url":null,"abstract":"In this single-arm pilot study, a novel regimen of post-transplant cyclophosphamide (PTCy), sirolimus, mycophenolate mofetil (MMF) and RGI-2001 was investigated to explore regulatory T-cell (T-reg) expansion in the setting of haploidentical allogeneic hematopoietic cell transplantation (HCT). RGI-2001 was infused at 100 ug/kg per dose, for six weekly doses. The primary endpoint was feasibility, assessed by the proportion of participants who were able to receive ≥4 doses of RGI-2001. Twenty-five participants enrolled. The primary endpoint was achieved by 80% of participants, deeming the regimen feasible. Longitudinal immune monitoring demonstrated recovery of T-reg subsets following HCT. The estimated probabilities of grades III-IV acute GVHD by day +180 was 12%, and moderate-severe chronic GVHD by 1 year was 28%. The regimen of PTCy, sirolimus, MMF and RGI-2001 was feasible. Future studies should evaluate optimized sequencing and dosing strategies to maximize the immunomodulatory effects of RGI-2001. This trial was registered at www.clinicaltrials.gov as NCT04473911.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes and tolerability of bendamustine dose reductions when used in combination with anti-CD20 antibody as initial therapy in elderly patients with indolent lymphoproliferative disorders. 苯达莫司汀联合抗cd20抗体作为老年惰性淋巴细胞增生性疾病患者初始治疗的结果和耐受性

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-20 DOI: 10.1080/10428194.2026.2745240

Jennifer Yao, Anna Johnston, Jared Fairbank, Melissa Armstrong, Kate Manos, David Mathers, Mark Hertzberg, Amanda Tey, Ashley Whitechurch, Miles Ma, Anthony Jeffrey, Catelyn Cashion, Nicholas Parkes, Yao Ly, Eliza A Hawkes, Adrian Yeung, Andrew Grigg

引用次数: 0

Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports. 口服阿扎胞苷作为有时限的、pcr依赖的维持治疗急性髓系白血病inv(16)：两例报告。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-15 DOI: 10.1080/10428194.2026.2747547

Sahana Kannan, Julia Jennings, Lloyd Hutchinson, Anne Higgins, Timothy Sannes, Shyam Ajay Patel, Jan Cerny, Laurie Pearson

{"title":"Oral azacitidine as time-limited, PCR-dependent maintenance in acute myeloid leukemia with inv(16): two case reports.","authors":"Sahana Kannan, Julia Jennings, Lloyd Hutchinson, Anne Higgins, Timothy Sannes, Shyam Ajay Patel, Jan Cerny, Laurie Pearson","doi":"10.1080/10428194.2026.2747547","DOIUrl":"https://doi.org/10.1080/10428194.2026.2747547","url":null,"abstract":"Core-binding factor acute myeloid leukemia (CBF-AML) in fit patients is treated with curative-intent induction chemotherapy followed by 3-4 cycles of high-dose cytarabine (HiDAC) consolidation. No standard therapy exists for patients with contraindications to HiDAC consolidation. Oral azacitidine is approved as indefinite maintenance therapy for intermediate/high risk AML but has not been studied in CBF-AML, nor in a time-limited fashion. We present two patients with CBF-AML who achieved morphologic remission after induction but had medical (case 1) or psychiatric (case 2) contraindications to HiDAC, therefore receiving oral azacitidine in a minimal residual disease (MRD)-guided, time-limited fashion. In case 1, drug-induced liver injury precluded HiDAC therapy; after four cycles, CBFB::MYH11 became PCR-undetectable, and azacitidine continued for a year. In case 2, a suicide attempt related to anticipated hospitalization precluded HiDAC; azacitidine was administered intermittently. Both patients remain MRD-negative 1.5 years post-treatment suggesting time-limited, MRD-guided azacitidine as a potential alternative to HiDAC consolidation.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-6"},"PeriodicalIF":2.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149195112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term mental health service utilization among patients with diffuse large B-cell lymphoma: a population-based study. 弥漫性大b细胞淋巴瘤患者长期心理健康服务利用：一项基于人群的研究

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-14 DOI: 10.1080/10428194.2026.2746186

Inna Y Gong, Matthew C Cheung, Kelvin K W Chan, Andrew Calzavara, Ning Liu, Hari S Raman, Oreofe O Odejide, Paul Kurdyak, Michael J Raphael, Anca Prica, Lee Mozessohn

{"title":"Long-term mental health service utilization among patients with diffuse large B-cell lymphoma: a population-based study.","authors":"Inna Y Gong, Matthew C Cheung, Kelvin K W Chan, Andrew Calzavara, Ning Liu, Hari S Raman, Oreofe O Odejide, Paul Kurdyak, Michael J Raphael, Anca Prica, Lee Mozessohn","doi":"10.1080/10428194.2026.2746186","DOIUrl":"https://doi.org/10.1080/10428194.2026.2746186","url":null,"abstract":"Mental health disorders are common in diffuse large B-cell lymphoma (DLBCL), yet long-term mental health service utilization (MHU) remains poorly characterized. We evaluated MHU rates and associated sociodemographic factors in patients undergoing curative treatment. This population-based retrospective matched-cohort study used Ontario administrative data; patients treated with rituximab-based chemotherapy (2005-2017) were matched 1:4 (age/sex) to non-cancer controls and followed up to 15 years. Difference-in-differences Poisson regression compared MHU between groups, adjusting for sociodemographic variables. Among 10,132 patients and 40,528 controls, DLBCL patients had significantly higher adjusted MHU at 5 years: outpatient visits (aRR 1.22), emergency visits (aRR 1.75), and hospitalizations (aRR 1.97). Elevated rates persisted at 10 and 15 years. Higher MHU was associated with younger age, female sex, lower income, and urban residence. DLBCL patients demonstrated persistently elevated MHU for up to 15 years post-treatment, underscoring the need for mental health integration into survivorship care.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging drug profile: bexobrutideg. 新出现的药物简介：bexobrutideg。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-11 DOI: 10.1080/10428194.2026.2743355

Tiana Huynh, Sonia Rodriguez-Rodriguez, Alexey V Danilov

引用次数: 0

Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis. 在venetoclax联合阿扎胞苷或地西他滨治疗新诊断的急性髓性白血病期间，唑和其他CYP3A4抑制剂联合给药的临床结果：一项系统回顾和荟萃分析。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-07 DOI: 10.1080/10428194.2026.2742608

Fernando De la Garza-Salazar, Diana Lorena Lankenau Vela, Daena Guadalupe Muñoz Cruz

{"title":"Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.","authors":"Fernando De la Garza-Salazar, Diana Lorena Lankenau Vela, Daena Guadalupe Muñoz Cruz","doi":"10.1080/10428194.2026.2742608","DOIUrl":"https://doi.org/10.1080/10428194.2026.2742608","url":null,"abstract":"Venetoclax plus azacitidine or decitabine (VEN-HMA) is a frontline option for newly diagnosed acute myeloid leukemia (AML). Venetoclax is metabolized by CYP3A4 and in practice is frequently coadministered with CYP3A4 inhibitors, yet whether this affects outcomes is unknown. We systematically searched four databases (PROSPERO CRD420251152772) for newly diagnosed AML treated with VEN-HMA reporting composite complete remission (CRc), invasive fungal infection or survival by CYP3A4-inhibitor status, through August 2026. Nineteen studies (2021-2026) were included, twelve contributing to the quantitative syntheses. Across five comparative cohorts, the pooled odds ratio for CRc was 0.81 (95% CI 0.58-1.13; I2=0%); among six single-arm cohorts, the pooled CRc proportion was 67.1% (62.0-71.9%), matching no-inhibitor and trial benchmarks (∼66-67%). Fungal infection was pooled but uninformative; survival was not pooled. Overall certainty was very low. Concomitant CYP3A4-inhibitor exposure was not associated with compromised remission, consistent with the feasibility of reduced-dose regimens pending prospective confirmation.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-17"},"PeriodicalIF":2.1,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed platelet recovery in lymphoma patients after autologous hematopoietic cell transplantation - risk factors and prognostic significance. 淋巴瘤患者自体造血细胞移植后血小板恢复延迟的危险因素及预后意义。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-07 DOI: 10.1080/10428194.2026.2738355

Antti Turunen, Outi Kuittinen, Ville Varmavuo, Esa Jantunen, Anu Partanen

引用次数: 0

Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies. Navitoclax单药治疗或联合ruxolitinib治疗JAK2抑制剂治疗的骨髓纤维化患者：来自2期REFINE和3期TRANSFORM-2研究的结果

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-07 DOI: 10.1080/10428194.2026.2739358

Raajit K Rampal, Claire N Harrison, Ruben Mesa, Alessandro M Vannucchi, Kazuya Shimoda, Andrew Perkins, Jacqueline S Garcia, Andreas Reiter, Atanas Radinoff, Fabrizio Pane, Francesca Palandri, Elza Lomaia, Sung-Eun Lee, Hun S Chuah, Francesco Passamonti, Guray Saydam, Mehmet Turgut, Sung-Soo Yoon, Earle E Bain, Hung Lam, Shilpa Jain, Jalaja Potluri, Jean-Jacques Kiladjian

引用次数: 0

Evaluating YouTube videos for Hodgkin lymphoma patient education. 评价YouTube视频对霍奇金淋巴瘤患者教育的作用。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-10-05 DOI: 10.1080/10428194.2026.2741486

Stephanie Quon, Sandy Lum-Wang, Paris-Ann Ingledew

引用次数: 0